- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05048966
Vergleich zweier Gruppen-Wellnessinterventionen für Personen mit neurologischen Erkrankungen und ihre Begleitpersonen
Vergleich zweier Gruppen-Wellnessinterventionen für Personen mit neurologischen Erkrankungen und ihre Begleitpersonen: Eine randomisierte klinische Studie
Approximately 5.3 million people live with a long-term disability resulting from a traumatic brain injury (TBI) and between 5-8% of those older than 60 suffer from Alzheimer's disease or other forms of dementia (ADRD). Consequences of these conditions can result in dramatic and persistent changes in functioning, impacting not only the patients, but also loved ones who become informal support persons. Many existing services help the family in the moment, but do not address long-term wellness. Thus, the purpose of this research study is to compare the effect of two different types of group wellness treatments for individuals with chronic mild TBI, moderate to severe TBI, and ADRD and their support persons.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The study will involve three sites, with a different clinical population targeted at each site. Kessler Foundation will serve as the Coordinating Center and will enroll individuals with moderate/severe TBI. Indiana University and University of Michigan will serve as partnering sites and will enroll individuals with chronic mild TBI and ADRD respectively. The research protocols at each site will be unique to the patient population, but harmonized through unified project goals: 1) to evaluate the efficacy of two different online group wellness treatments designed to improve self-efficacy and quality of life, and 2) to determine whether patient neurobehavioral functioning moderates the relationship between treatment outcomes and burden in caregivers, and 3) to determine the neural, behavioral, and blood biomarkers that best predict treatment efficacy. It is expected that findings generated from this study will lead to improved holistic approaches for brain injury and dementia systems of care.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Diana Maloku, B.S.
- Telefonnummer: 973-324-8393
- E-Mail: dmaloku@kesslerfoundation.org
Studienorte
-
-
New Jersey
-
East Hanover, New Jersey, Vereinigte Staaten, 07936
- Rekrutierung
- Kessler Foundation
-
Kontakt:
- Matthew Weiner
- Telefonnummer: 973-324-3515
- E-Mail: mweiner@kesslerfoundation.org
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
For individuals with moderate/severe TBI:
Inclusion Criteria:
- age 18-70
- at least 4 months post injury
- can read and speak English fluently
- has a support person who is willing to participate in the study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than TBI
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For individuals with chronic mild TBI:
Inclusion Criteria:
- age 18-70
- at least 3 months post-injury
- can read and speak English fluently
- has a support person who is willing to participate in the study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than mild TBI
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For Individuals with Alzheimer's Disease Related Dementias (ADRD)
Inclusion Criteria:
- age 65 and older
- at least one-year post-diagnosis
- can read and speak English fluently
- has a support person who is willing to participate in this study
Exclusion Criteria:
- has had a prior stroke or neurological disease other than ADRD
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
For Support Persons:
Inclusion Criteria:
- is the support person of an individual with moderate/severe TBI, chronic mild TBI or ADRD who is willing to participate in the study
- can read and speak English fluently
Exclusion Criteria:
- has a significant neurological history (e.g. stroke or multiple sclerosis)
- has unstable or uncontrolled seizures
- has been hospitalized due to a significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) in the past three months
- current alcohol and/or drug use that interferes with ability to carry out common everyday functions
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Group Wellness Class 1
|
Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours. |
|
Aktiver Komparator: Group Wellness Class 2
|
Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change on Self-Efficacy Questionnaire (SEQ)
Zeitfenster: 12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
self-report instrument that assesses an individual's and support person's self-efficacy as it relates to their ability to manage the effects of the neurologic conditions on their daily functioning |
12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
|
Change on Satisfaction with Life Scale (SWLS)
Zeitfenster: 12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
self-report measure that examines life satisfaction component of subjective well-being and quality of life |
12 weeks (between pre- and post-testing) and 6 months (between post-testing and 6 month follow-up)
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Psychische Störungen
- Wunden und Verletzungen
- Neurokognitive Störungen
- Tauopathien
- Neurodegenerative Krankheiten
- Kraniozerebrales Trauma
- Trauma, Nervensystem
- Kopfverletzungen, geschlossen
- Wunden, nicht durchdringend
- Hirnverletzungen
- Hirnverletzungen, traumatisch
- Alzheimer Erkrankung
- Gehirnerschütterung
- Demenz
Andere Studien-ID-Nummern
- R-1157-21
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .